688 related articles for article (PubMed ID: 27660463)
1. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Wang X; Goldstein D; Crowe PJ; Yang JL
Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
[TBL] [Abstract][Full Text] [Related]
2. Next-Generation
Sullivan I; Planchard D
Front Med (Lausanne); 2016; 3():76. PubMed ID: 28149837
[TBL] [Abstract][Full Text] [Related]
3. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
4. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
5. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Liao BC; Lin CC; Yang JC
Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
[TBL] [Abstract][Full Text] [Related]
6. Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.
Duggirala KB; Lee Y; Lee K
Biomol Ther (Seoul); 2022 Jan; 30(1):19-27. PubMed ID: 34074804
[TBL] [Abstract][Full Text] [Related]
7. [Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].
Asami K
Gan To Kagaku Ryoho; 2014 May; 41(5):533-8. PubMed ID: 24916999
[TBL] [Abstract][Full Text] [Related]
8. Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer.
Zhang H
Drug Des Devel Ther; 2016; 10():3867-3872. PubMed ID: 27920501
[TBL] [Abstract][Full Text] [Related]
9. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
10. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
11. An Observational Study of Acquired
Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
Front Oncol; 2020; 10():1481. PubMed ID: 33014788
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.
Hirsh V
BioDrugs; 2015 Jun; 29(3):167-83. PubMed ID: 26123538
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Lee Y; Wang Y; James M; Jeong JH; You M
Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
[TBL] [Abstract][Full Text] [Related]
14. Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.
Costa DB; Kobayashi SS
Transl Lung Cancer Res; 2015 Dec; 4(6):809-15. PubMed ID: 26798593
[TBL] [Abstract][Full Text] [Related]
15. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
16. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice.
Slobbe P; Windhorst AD; Stigter-van Walsum M; Smit EF; Niessen HG; Solca F; Stehle G; van Dongen GA; Poot AJ
EJNMMI Res; 2015; 5():14. PubMed ID: 25853020
[TBL] [Abstract][Full Text] [Related]
17. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.
Minari R; Bordi P; Tiseo M
Transl Lung Cancer Res; 2016 Dec; 5(6):695-708. PubMed ID: 28149764
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
19. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC.
Nelson V; Ziehr J; Agulnik M; Johnson M
Onco Targets Ther; 2013; 6():135-43. PubMed ID: 23493883
[TBL] [Abstract][Full Text] [Related]
20. Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Andrews Wright NM; Goss GD
Transl Lung Cancer Res; 2019 Nov; 8(Suppl 3):S247-S264. PubMed ID: 31857949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]